Nutex Health (NUTX) Research & Development (2019 - 2022)

Nutex Health has reported Research & Development for 4 years, with the latest figure at $73750.0 in Q1 2022.

• Quarterly Research & Development fell 3.87% year-over-year to $73750.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $229985.0 (down 10.69% YoY) and the FY2021 annual result came in at $285880.0, down 48.7% from the prior year.
• Research & Development retreated to $73750.0 in Q1 2022 per NUTX's latest filing, from $77265.0 in the prior quarter.
• Over five years, Research & Development peaked at $282462.0 in Q2 2019 and troughed at $6704.0 in Q2 2021.
• A 4-year average of $97107.3 and a median of $73827.0 in 2020 frame the typical range for Research & Development.
• The sharpest annual moves came in 2020 and 2021: Research & Development surged 81.24% in 2020, then sank 87.27% in 2021.
• Over 4 years, Research & Development stood at $196632.0 in 2019, then tumbled by 72.39% to $54296.0 in 2020, then jumped by 42.3% to $77265.0 in 2021, then fell by 4.55% to $73750.0 in 2022.
• According to Business Quant data, Research & Development over the past three periods registered $73750.0, $77265.0, and $72266.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.